Merck join the SGC with multi-million dollar contribution.

Merck have announced a contribution of C$7.5 million to the Structural Genomics Consortium (SGC), joining as a member organisation.

The supported project focus on per-competitive research to develop small inhibitory molecules called chemical probes to study epigenetic mechanisms of regulation. In collaboration with leading clinical institutions in Ontario and around the world, use of the probes will expand the understanding of biology in multiple disease areas, particularly cancer and inflammatory diseases.

“At Merck, we strive to identify and support research areas that will have the most impact on fulfilling the unmet medical needs of patients, who are at the core of everything we do. In Canada, Merck is very pleased to be able to encourage innovation and research across an established SGC collaborative network of more than 250 academic laboratories at leading institutions,” said Chirfi Guindo, President and Managing Director, Merck Canada Inc.


The full release can be found here via the SGC.